文献速递冠心病

单细胞基因组学揭示平滑肌细胞表型转换中的新细胞状态及动脉粥样硬化潜在治疗靶点

Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human.
PubMed 文献 · Circulation · 2020-09-23

该研究结合小鼠和人类动脉粥样硬化斑块的平滑肌细胞命运图谱与单细胞RNA测序,发现平滑肌细胞在动脉粥样硬化过程中经过一种中间细胞状态(SEM细胞),该状态具有多能性,可分化为巨噬细胞样和纤维软骨样细胞,也可返回平滑肌细胞表型。维甲酸信号通路调控这一转变,激活该通路可减少斑块负荷并促进纤维帽稳定性。

要点

  • 平滑肌细胞在动脉粥样硬化中经SEM中间状态转分化,人类斑块中亦存在。
  • 维甲酸信号通路调控平滑肌细胞向SEM细胞转变,全反式维甲酸可阻断该过程。
  • 激活维甲酸信号可减轻动脉粥样硬化负担并促进纤维帽稳定性。

核心结论

  • 平滑肌细胞通过SEM中间状态发生表型转换,维甲酸信号通路是潜在治疗靶点。

研究设计与样本

  • 结合小鼠和人类动脉粥样硬化斑块的平滑肌细胞命运映射与单细胞RNA测序,并进行细胞生物学实验、整合人类基因组学和药理学研究。

主要发现

  • 平滑肌细胞在动脉粥样硬化中转变为SEM中间细胞状态,该状态也存在于人类颈动脉和冠状动脉斑块中。
  • SEM细胞具有多能性,可分化为巨噬细胞样和纤维软骨样细胞,也可返回平滑肌细胞表型。
  • 维甲酸信号通路被鉴定为平滑肌细胞向SEM细胞转变的调节因子,在症状性人类动脉粥样硬化中失调。
  • 人类基因组学显示冠状动脉疾病全基因组关联研究信号在维甲酸信号靶基因位点富集。
  • 全反式维甲酸阻断平滑肌细胞向SEM细胞转变,减少动脉粥样硬化负担并促进纤维帽稳定性。

临床怎么用

  • 全反式维甲酸(抗急性早幼粒细胞白血病药物)可能通过激活维甲酸信号通路抑制平滑肌细胞转变,减轻动脉粥样硬化并稳定斑块。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Smooth muscle cells (SMCs) play significant roles in atherosclerosis via phenotypic switching, a pathological process in which SMC dedifferentiation, migration, and transdifferentiation into other cell types. Yet how SMCs contribute to the pathophysiology of atherosclerosis remains elusive. METHODS: To reveal the trajectories of SMC transdifferentiation during atherosclerosis and to identify molecular targets for disease therapy, we combined SMC fate mapping and single-cell RNA sequencing of both mouse and human atherosclerotic plaques. We also performed cell biology experiments on isolated SMC-derived cells, conducted integrative human genomics, and used pharmacological studies targeting SMC-derived cells both in vivo and in vitro. RESULTS: We found that SMCs transitioned to an intermediate cell state during atherosclerosis, which was also found in human atherosclerotic plaques of carotid and coronary arteries. SMC-derived intermediate cells, termed "SEM" cells (stem cell, endothelial cell, monocyte), were multipotent and could differentiate into macrophage-like and fibrochondrocyte-like cells, as well as return toward the SMC phenotype. Retinoic acid (RA) signaling was identified as a regulator of SMC to SEM cell transition, and RA signaling was dysregulated in symptomatic human atherosclerosis. Human genomics revealed enrichment of genome-wide association study signals for coronary artery disease in RA signaling target gene loci and correlation between coronary artery disease risk alleles and repressed expression of these genes. Activation of RA signaling by all-trans RA, an anticancer drug for acute promyelocytic leukemia, blocked SMC transition to SEM cells, reduced atherosclerotic burden, and promoted fibrous cap stability. CONCLUSIONS: Integration of cell-specific fate mapping, single-cell genomics, and human genetics adds novel insights into the complexity of SMC biology and reveals regulatory pathways for therapeutic targeting of SMC transitions in atherosclerotic cardiovascular disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Pan H, Xue C, Auerbach BJ, et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation. 2020. PMID: 32962412. doi:10.1161/CIRCULATIONAHA.120.048378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。